P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.
During the past few decades, researchers have been looking for parameters with an impact on the prognosis of patients with astrocytic tumors. p53 is one of the most widely investigated molecules in human gliomas. We aimed to comprehensively review the evidence for the prognostic usefulness of p53 immunohistochemical expression in paraffin-embedded tissue specimens from diffusely infiltrating astrocytomas. We conducted a systematic review of the PubMed database through December 2007 to identify cohort studies that evaluated p53 immunohistochemical expression as a prognostic marker for human astrocytomas. Estimates of significance were extracted from association tests and hazard ratios with 95% CI from actuarial curves and Cox regression analyses. A meta-analysis was performed on the studies that applied Cox models and had adjusted the hazard ratio of p53 expression with tumor grade and patients' age. We reviewed 44 publications (including 3,627 patients), 14 of which included the estimates (HR and 95% CI) derived from Cox regression. Descriptive analysis showed that most of the published articles did not contain information on important variables such as sex and age (missing from 25% and 11% of studies, respectively), previous treatment, tissue-retrieval and follow-up period (56%). The quantitative synthesis showed that p53 expression is not a significant prognostic factor (combined HR = 1.034, P = 0.531). There was no significant between-study heterogeneity and publication bias. A second meta-analysis performed only on glioblastomas showed that the overall risk of mortality in these tumors was -0.123 (-0.346 to 0.100) and was not statistically significant. After almost 20 years of research, published evidence does not substantiate the usefulness of p53 immunohistochemical expression as a prognostic marker in patients with astrocytic neoplasms.
Levidou
Georgia
G
Medical School, Department of Pathology, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece. glevidou@yahoo.gr
El-Habr
Elias
E
Saetta
Angelica A
AA
Bamias
Christine
C
Katsouyanni
Klea
K
Katsougiannis
Klea
K
Patsouris
Efstratios
E
Korkolopoulou
Penelope
P
D000328:Adult; D001254:Astrocytoma / Q000175:diagnosis* / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D015415:Biomarkers; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53
Cancer Treat Rev. 2000 Feb;26(1):67-73
10660492
Anticancer Res. 2006 Mar-Apr;26(2B):1351-7
16619544
Cancer. 1997 Jul 15;80(2):242-9
9217037
Clin Neuropathol. 1997 Nov-Dec;16(6):332-6
9401801
Br J Neurosurg. 2002 Aug;16(4):335-42
12389885
Br J Neurosurg. 1998 Aug;12(4):318-24
10070423
JAMA. 1994 Jul 20;272(3):234-7
8022043
Cancer. 1999 Aug 15;86(4):672-83
10440696
Neurosurgery. 1995 Aug;37(2):246-54
7477776
APMIS. 1994 Oct;102(10):786-92
7826609
Cancer Res. 2001 Feb 1;61(3):1122-8
11221842
J Neurooncol. 1997 Oct;35(1):13-28
9266437
J Neurooncol. 2002 Jul;58(3):217-36
12187957
J Clin Pathol. 2001 Nov;54(11):860-5
11684721
J Neurosurg. 1997 Jan;86(1):121-30
8988090
Cancer. 2003 Feb 1;97(3):644-8
12548606
Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8
9821169
Clin Neuropathol. 1996 Mar-Apr;15(2):67-73
8925599
Clin Neuropathol. 1997 Jul-Aug;16(4):220-6
9266149
Eur Respir J. 2001 Oct;18(4):705-19
11716177
J Clin Oncol. 2001 Mar 15;19(6):1865-78
11251019
Clin Cancer Res. 2006 Jan 15;12(2):473-7
16428489
Br J Cancer. 1997;75(9):1269-78
9155045
Br J Cancer. 2004 Nov 1;91(9):1678-86
15494720
J Neurooncol. 2001 Dec;55(3):195-204
11859975
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
J Neurooncol. 2006 Oct;80(1):49-55
16645716
Brain Pathol. 2006 Oct;16(4):273-86
17107596
Diagn Mol Pathol. 1994 Dec;3(4):240-5
7866633
Mol Cell. 2004 Mar 26;13(6):879-86
15053880
Br J Neurosurg. 1995 Apr;9(2):143-9
7632359
J Natl Cancer Inst. 1994 Jun 1;86(11):829-35
8182763
Kaohsiung J Med Sci. 1998 Oct;14(10):607-15
9819502
Health Technol Assess. 2003;7(5):1-162
12633526
Genes Dev. 2007 Nov 1;21(21):2683-710
17974913
Cancer Res. 1994 Sep 15;54(18):4855-78
8069852
J Clin Oncol. 2004 Mar 15;22(6):975-7
14981108
Cancer. 2003 Feb 15;97(4):1063-71
12569607
Clin Cancer Res. 2002 Jan;8(1):180-7
11801556
J Neurol Neurosurg Psychiatry. 1995 Oct;59(4):413-9
7561922
J Neurooncol. 2002 Jul;58(3):203-15
12187956
Br J Cancer. 1994 Mar;69(3):586-91
8123492
Adv Cancer Res. 2000;77:81-137
10549356
Int J Cancer. 1994 Feb 1;56(3):347-53
7906253
Clin Cancer Res. 1995 Dec;1(12):1617-22
9815964
Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):91-6
16540738
Arq Neuropsiquiatr. 2004 Jun;62(2A):262-70
15235729
Clin Neuropathol. 2000 Sep-Oct;19(5):230-4
11048748
Clin Cancer Res. 2002 May;8(5):1117-24
12006527
Lancet Oncol. 2005 Sep;6(9):678-86
16129368
Oncol Rep. 2002 Jul-Aug;9(4):703-7
12066196
Neuropathol Appl Neurobiol. 1999 Apr;25(2):134-42
10216001
Neurosurgery. 1998 Apr;42(4):724-9
9574635
Lancet. 1993 Feb 13;341(8842):418-22
8094183
Pediatr Neurosurg. 2005 Nov-Dec;41(6):292-9
16293948
J Neurooncol. 2006 Jun;78(2):123-7
16614946
Nat Clin Pract Urol. 2005 Aug;2(8):416-22
16482653
Crit Rev Neurosurg. 1998 Sep 14;8(5):269-74
9732540
J Pathol. 1992 Apr;166(4):329-30
1517889
Pathol Res Pract. 1998;194(12):831-6
9894248
Stat Med. 1998 Dec 30;17(24):2815-34
9921604
Nature. 2000 Nov 16;408(6810):307-10
11099028
Br J Cancer. 1992 Aug;66(2):373-85
1503912
Zentralbl Neurochir. 2003;64(1):30-6
12582944
Br J Cancer. 2004 Apr 19;90(8):1572-6
15083187